Immunovant (NASDAQ:IMVT – Get Rating) had its target price increased by equities research analysts at Bank of America from $26.00 to $28.00 in a research note issued to investors on Tuesday, The Fly reports. Bank of America‘s price target points to a potential upside of 17.55% from the stock’s current price. IMVT has been the […]